<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03397030</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20160604HU</org_study_id>
    <nct_id>NCT03397030</nct_id>
  </id_info>
  <brief_title>Impact of Exercise on Prognostic Biomarkers Related to Prostate Cancer</brief_title>
  <official_title>Impact of a Home-based Exercise Program on Prognostic Biomarkers in Men With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to demonstrate the impact of a home based exercise program versus
      wait-list control to modulate circulating prognostic biomarkers in men with prostate cancer
      under active surveillance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate cancer (PCa) is the most common non-skin cancer effecting American males. Several
      reports suggest that physical activity after cancer diagnosis is associated with better
      cancer- specific and overall survival in individuals diagnosed with PCa. There is a growing
      body of evidence for lifestyle interventions that aim to promote physical activity as having
      the potential to counter some of the adverse effects of cancer treatments, disease
      progression and other health outcomes. Exercise performed 2-3 times a week has been shown to
      improve physical fitness, functional performance, and quality of life in men with PCa;
      however, few men with PCa exercise regularly and do not meet national physical activity
      guidelines. A potential explanation on the lack of exercise in men with PCa is the absence of
      a structured, home-based, exercise program. While studies have shown positive effects of
      exercise in men with PCa, little is known about how physical activity effects tumor
      physiology in men with PCa. The primary objective of this pilot study is to gather
      preliminary data regarding the impact of a novel, home-based exercise program on PCa
      biomarkers associated with recurrence and metastasis of PCa in men under active surveillance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study is designed randomized controlled, 2 arm parallel group pilot study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking was used in this study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in concentration of circulating Prognostic Biomarkers</measure>
    <time_frame>Baseline Visit, Week 12 visit, Week 18 visit and Week 24 visit.</time_frame>
    <description>Analyze concentrations of Prostate-specific antigen (PSA), Prostate-specific membrane antigen (PSMA), Early prostate cancer antigen (EPCA), Urokinase plasminogen activator (uPA), and Urokinase plasminogen activator receptor (uPAR) in serum collected at each visit with research staff.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Salivary Biomarkers</measure>
    <time_frame>Baseline visit, Week 12 visit, Week 18 visit, and Week 24 visit.</time_frame>
    <description>Analyze participants level of cancer-related Fatigue through the concentration of Fatigue Biomarker Index in participants saliva taken at each visit with research staff.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Improvement in Distance Walked</measure>
    <time_frame>Baseline and Week 24 visits.</time_frame>
    <description>A 6-minute walk will be will be completed by participants during their initial and last appointments with research staff.</description>
  </other_outcome>
  <other_outcome>
    <measure>Improvement in Body Composition</measure>
    <time_frame>Baseline visit, Week 12 visit, Week 18 visit, and Week 24 visit.</time_frame>
    <description>Changes in participant's body composition will be measured at each visit with research staff.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostatic Neoplasm</condition>
  <arm_group>
    <arm_group_label>Home-Based Exercise Program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will complete a prescribed home-based exercise program and will follow up with research staff at the UT Health San Antonio School of Nursing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Waitlist-Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants assigned to this group will be asked to maintain normal activity and visit the UT Health San Antonio School of Nursing for research appointments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Home-Based Exercise Program</intervention_name>
    <description>The intervention will include a combination of both aerobic and body-weight based exercises. The aerobic portion of the intervention will include 5 days of light to moderate intensity walking for 30 mins. Intensity will be set at 40-60% of the individual's heart rate reserve. The body-weight based exercises will be done 3 times a week and will consist of 3 sets of 15 reps of bodyweight squats, incline push-ups, and hip thrusts. If these exercises cannot be performed, lower intensity exercises such as sit-to-stand, wall push up and pelvic tilt can be replaced. Individuals in this group will be given a pocket guide with instructions on how to safely perform the exercises and document their completion.</description>
    <arm_group_label>Home-Based Exercise Program</arm_group_label>
    <other_name>Exercise Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men aged 40 or older

          -  Diagnosed with prostate cancer

          -  Under active surveillance

          -  Subjects willing and able to provide consent to participating in the study

        Exclusion Criteria:

          -  severe cardiac disease (New York Heart Association class III or greater)

          -  angina

          -  severe osteoporosis

          -  uncontrolled hypertension (blood pressure &gt; 160/95mm Hg)

          -  uncontrolled sinus tachycardia (&gt; 120 beats per minute)

          -  uncontrolled congestive heart failure third-degree atrio-ventricular heart block,
             active pericarditis or myocarditis, recent embolism, thrombophlebitis, deep vein
             thrombosis, resting ST displacement (&gt; 3mm), uncontrolled diabetes, uncontrolled pain,
             cognitive impairment, history of falls due to balance impairment or lost of
             consciousness,

          -  severe neuromusculoskeletal conditions that limit their ability to perform walking
             exercise (including ataxia, peripheral or sensory neuropathy, unstable bone lesion,
             severe arthritis, lower limb fractures within 6 months, lower limb amputation).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Participants are required to have prostate cancer under active surveillance.</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darpan Patel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Health San Antonio School of Nursing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Vardeman</last_name>
    <phone>817-313-8263</phone>
    <email>VardemanS@livemail.uthscsa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amber Gallegos</last_name>
    <phone>210-606-2437</phone>
    <email>gallegosa4@uthscsa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UT Health San Antonio School of Nursing</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Vardeman</last_name>
      <phone>817-313-8263</phone>
      <email>VardemanS@livemail.uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amber Gallegos</last_name>
      <phone>210-606-2437</phone>
      <email>gallegosa4@uthscsa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Darpan I Patel, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol. 2010 Jan 10;28(2):340-7. doi: 10.1200/JCO.2009.23.2488. Epub 2009 Nov 30.</citation>
    <PMID>19949016</PMID>
  </reference>
  <reference>
    <citation>Keogh JW, MacLeod RD. Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: a systematic review. J Pain Symptom Manage. 2012 Jan;43(1):96-110. doi: 10.1016/j.jpainsymman.2011.03.006. Epub 2011 Jun 2. Review.</citation>
    <PMID>21640547</PMID>
  </reference>
  <reference>
    <citation>Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression. J Clin Oncol. 2005 Nov 10;23(32):8152-60. Review.</citation>
    <PMID>16278466</PMID>
  </reference>
  <reference>
    <citation>Sonn GA, Aronson W, Litwin MS. Impact of diet on prostate cancer: a review. Prostate Cancer Prostatic Dis. 2005;8(4):304-10. Review.</citation>
    <PMID>16130015</PMID>
  </reference>
  <reference>
    <citation>Pekmezi DW, Demark-Wahnefried W. Updated evidence in support of diet and exercise interventions in cancer survivors. Acta Oncol. 2011 Feb;50(2):167-78. doi: 10.3109/0284186X.2010.529822. Epub 2010 Nov 24. Review.</citation>
    <PMID>21091401</PMID>
  </reference>
  <reference>
    <citation>Galvão DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, Suzuki K, Yamaya K, Newton RU. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc. 2006 Dec;38(12):2045-52.</citation>
    <PMID>17146309</PMID>
  </reference>
  <reference>
    <citation>Galvão DA, Spry N, Denham J, Taaffe DR, Cormie P, Joseph D, Lamb DS, Chambers SK, Newton RU. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol. 2014 May;65(5):856-64. doi: 10.1016/j.eururo.2013.09.041. Epub 2013 Oct 3.</citation>
    <PMID>24113319</PMID>
  </reference>
  <reference>
    <citation>Galvão DA, Spry N, Taaffe DR, Denham J, Joseph D, Lamb DS, Levin G, Duchesne G, Newton RU. A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial. BMC Cancer. 2009 Dec 2;9:419. doi: 10.1186/1471-2407-9-419.</citation>
    <PMID>19951446</PMID>
  </reference>
  <reference>
    <citation>Keogh JW, Shepherd D, Krägeloh CU, Ryan C, Masters J, Shepherd G, MacLeod R. Predictors of physical activity and quality of life in New Zealand prostate cancer survivors undergoing androgen-deprivation therapy. N Z Med J. 2010 Nov 5;123(1325):20-9.</citation>
    <PMID>21317957</PMID>
  </reference>
  <reference>
    <citation>Mitchell SA, Beck SL, Hood LE, Moore K, Tanner ER. Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs. 2007 Feb;11(1):99-113. Review. Update in: Clin J Oncol Nurs. 2014;18 Suppl:38-58.</citation>
    <PMID>17441401</PMID>
  </reference>
  <reference>
    <citation>Monga U, Garber SL, Thornby J, Vallbona C, Kerrigan AJ, Monga TN, Zimmermann KP. Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy. Arch Phys Med Rehabil. 2007 Nov;88(11):1416-22.</citation>
    <PMID>17964881</PMID>
  </reference>
  <reference>
    <citation>Bellizzi KM, Rowland JH, Jeffery DD, McNeel T. Health behaviors of cancer survivors: examining opportunities for cancer control intervention. J Clin Oncol. 2005 Dec 1;23(34):8884-93.</citation>
    <PMID>16314649</PMID>
  </reference>
  <reference>
    <citation>Coups EJ, Ostroff JS. A population-based estimate of the prevalence of behavioral risk factors among adult cancer survivors and noncancer controls. Prev Med. 2005 Jun;40(6):702-11.</citation>
    <PMID>15850868</PMID>
  </reference>
  <reference>
    <citation>Hansen PA, Dechet CB, Porucznik CA, LaStayo PC. Comparing eccentric resistance exercise in prostate cancer survivors on and off hormone therapy: a pilot study. PM R. 2009 Nov;1(11):1019-24. doi: 10.1016/j.pmrj.2009.09.016.</citation>
    <PMID>19942188</PMID>
  </reference>
  <reference>
    <citation>Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, Venner PM, Quinney HA, Jones LW, D'Angelo ME, Wells GA. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003 May 1;21(9):1653-9.</citation>
    <PMID>12721238</PMID>
  </reference>
  <reference>
    <citation>Obort AS, Ajadi MB, Akinloye O. Prostate-specific antigen: any successor in sight? Rev Urol. 2013;15(3):97-107. Review.</citation>
    <PMID>24223021</PMID>
  </reference>
  <reference>
    <citation>Murphy GP, Kenny GM, Ragde H, Wolfert RL, Boynton AL, Holmes EH, Misrock SL, Bartsch G, Klocker H, Pointner J, Reissigl A, McLeod DG, Douglas T, Morgan T, Gilbaugh J Jr. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. Urology. 1998 May;51(5A Suppl):89-97.</citation>
    <PMID>9610563</PMID>
  </reference>
  <reference>
    <citation>Zhao Z, Ma W, Zeng G, Qi D, Ou L, Liang Y. Preoperative serum levels of early prostate cancer antigen (EPCA) predict prostate cancer progression in patients undergoing radical prostatectomy. Prostate. 2012 Feb;72(3):270-9. doi: 10.1002/pros.21428. Epub 2011 May 31.</citation>
    <PMID>21630293</PMID>
  </reference>
  <reference>
    <citation>Gupta A, Lotan Y, Ashfaq R, Roehrborn CG, Raj GV, Aragaki CC, Montorsi F, Shariat SF. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol. 2009 May;55(5):1124-33. doi: 10.1016/j.eururo.2008.06.054. Epub 2008 Jun 23.</citation>
    <PMID>18585843</PMID>
  </reference>
  <reference>
    <citation>Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, Slawin KM. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol. 2007 Feb 1;25(4):349-55.</citation>
    <PMID>17264329</PMID>
  </reference>
  <reference>
    <citation>Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A. Tumor markers in prostate cancer I: blood-based markers. Acta Oncol. 2011 Jun;50 Suppl 1:61-75. doi: 10.3109/0284186X.2010.542174. Review.</citation>
    <PMID>21604943</PMID>
  </reference>
  <reference>
    <citation>Chen CL, Mahalingam D, Osmulski P, Jadhav RR, Wang CM, Leach RJ, Chang TC, Weitman SD, Kumar AP, Sun L, Gaczynska ME, Thompson IM, Huang TH. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate. 2013 Jun;73(8):813-26. doi: 10.1002/pros.22625. Epub 2012 Dec 31.</citation>
    <PMID>23280481</PMID>
  </reference>
  <reference>
    <citation>Gupta D, Lis CG, Grutsch JF. The relationship between cancer-related fatigue and patient satisfaction with quality of life in cancer. J Pain Symptom Manage. 2007 Jul;34(1):40-7. Epub 2007 May 25.</citation>
    <PMID>17532179</PMID>
  </reference>
  <reference>
    <citation>Campos MP, Hassan BJ, Riechelmann R, Del Giglio A. Cancer-related fatigue: a practical review. Ann Oncol. 2011 Jun;22(6):1273-9. doi: 10.1093/annonc/mdq458. Epub 2011 Feb 16. Review.</citation>
    <PMID>21325448</PMID>
  </reference>
  <reference>
    <citation>Michael DJ, Daugherty S, Santos A, Ruby BC, Kalns JE. Fatigue biomarker index: an objective salivary measure of fatigue level. Accid Anal Prev. 2012 Mar;45 Suppl:68-73. doi: 10.1016/j.aap.2011.09.029. Epub 2011 Oct 10.</citation>
    <PMID>22239935</PMID>
  </reference>
  <reference>
    <citation>Kalns J, Baskin J, Reinert A, Michael D, Santos A, Daugherty S, Wright JK. Predicting success in the tactical air combat party training pipeline. Mil Med. 2011 Apr;176(4):431-7.</citation>
    <PMID>21539166</PMID>
  </reference>
  <reference>
    <citation>Zoukhri D, Kublin CL. Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjögren's syndrome. Invest Ophthalmol Vis Sci. 2001 Apr;42(5):925-32.</citation>
    <PMID>11274068</PMID>
  </reference>
  <reference>
    <citation>Lubeck DP, Litwin MS, Henning JM, Stoddard ML, Flanders SC, Carroll PR. Changes in health-related quality of life in the first year after treatment for prostate cancer: results from CaPSURE. Urology. 1999 Jan;53(1):180-6.</citation>
    <PMID>9886609</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2018</study_first_submitted>
  <study_first_submitted_qc>January 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2018</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Darpan Patel</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

